Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | CNR2 | P34972 | 2/20 | 0.48 |
| ▸ | APP | P05067 | 3/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2085892 | 0.84 | RAB9A (0.50) | RAB9AHPGDNPC1PTGS1PTGS2 | |
| SCHEMBL2088899 | 0.83 | RAB9A (0.43) | RAB9AHPGDNPC1CNR2PTGS1 | |
| SCHEMBL2436690 | 0.83 | PTGS1 (0.54) | NPC1APPPTGS1PTGS2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL2086035 | 0.82 | RAB9A (0.49) | RAB9AHPGDNPC1PTGS1PTGS2 | |
| SCHEMBL2087833 | 0.81 | PTGS1 (0.45) | RAB9AHPGDNPC1PTGS1PTGS2 | |
| SCHEMBL2087968 | 0.81 | PTGS1 (0.51) | RAB9ANPC1CNR2PTGS1PTGS2 | |
| SCHEMBL3365520 | 0.80 | NPC1 (0.65) | RAB9AHPGDNPC1ALDH1A1MAPT | |
| SCHEMBL2086415 | 0.79 | RXFP1 (0.47) | RAB9ANPC1CNR2APPPTGS1 | |
| SCHEMBL1728496 | 0.79 | PTGS1 (0.50) | RAB9AHPGDNPC1CNR2APP | |
| SCHEMBL2087802 | 0.79 | PTGS1 (0.46) | RAB9ANPC1CNR2PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143420-A1 | 2-BENZOYLIMIDAZOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-06-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143420-A1 | 2-BENZOYLIMIDAZOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | NR4A2, NR4A3, NCOR1 | RAB9A 3310/4885HPGD 2403/4885NPC1 791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.